Clinical Trials Logo

Peritoneal Mesothelioma clinical trials

View clinical trials related to Peritoneal Mesothelioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06057935 Recruiting - Mesothelioma Clinical Trials

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Start date: September 21, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

NCT ID: NCT05337735 Recruiting - Clinical trials for Small Cell Lung Cancer

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Start date: August 5, 2022
Phase: Phase 2
Study type: Interventional

To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.

NCT ID: NCT04847063 Recruiting - Ovarian Cancer Clinical Trials

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

Start date: October 19, 2021
Phase: Phase 1
Study type: Interventional

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is heated chemotherapy that washes the abdomen. CRS and HIPEC may help people with peritoneal carcinomatosis. These are tumors that have spread to the lining of the abdomen from other cancers. Researchers think they can improve results of CRS and HIPEC by choosing the chemotherapy drugs used in HIPEC. Objective: To see if HIPEC after CRS can be improved, by testing different chemotherapy drugs, using a model called the SMART (Sample Microenvironment of Resected Metastatic Tumor) System. Eligibility: Adults ages 18 and older who have peritoneal carcinomatosis that cannot be fully removed safely with surgery. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Computed tomography (CAT) scan Other imaging scans, as needed Electrocardiogram (EKG) Tumor biopsy, if needed Laparoscopy. Small cuts will be made in the abdomen. A tube with a light and a camera will be used to see their organs. Some screening tests will be repeated in the study. Participants will enroll in NIH protocol #13C0176. This allows their tumor samples to be used in future research. Participants will have CRS. As many of their visible tumors will be removed as possible. They will also have HIPEC. Two thin tubes will be put in their abdomen. They will get chemotherapy through one tube. It will be drained out through the other tube. They will be in the hospital for 7-21 days after surgery. Participants will give tumor, blood, and fluid samples for research. They will complete surveys about their health and quality of life. Participants will have follow-up visits over 5 years....

NCT ID: NCT03875144 Recruiting - Clinical trials for Peritoneal Carcinomatosis

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

MESOTIP
Start date: August 14, 2020
Phase: Phase 2
Study type: Interventional

MESOTIP is a randomized trial evaluating the association of PIPAC and systemic chemotherapy versus systemic chemotherapy alone as 1st-line treatment of Malignant Peritoneal Mesothelioma In this study, patients in the experimental arm will be treated by 4 PIPAC (Cisplatine+Doxorubicine) alternating with 6 cycles of standard intravenous chemotherapy (Cisplatine+Pemetrexed). MESOTIP aim to show an improvement of the overall survival in the experimental arm.

NCT ID: NCT02588131 Recruiting - Clinical trials for Pleural Mesothelioma

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This phase 2, open-label, single arm study aims to evaluate the efficacy of tremelimumab in combination with the anti-PD-L1 MEDI4736 in patients with unresectable malignant mesothelioma subjects

NCT ID: NCT01617382 Recruiting - Clinical trials for Peritoneal Carcinomatosis

Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed

HIPEC
Start date: May 2012
Phase:
Study type: Observational

The purpose of this study is to register the follow-up data of patients who, because of a peritoneal surface malignancy, will undergo cytoreductive surgery and HIPEC.